Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

While great strides have been made in treating children with acute leukemia, some children continue to do poorly. For example, children of Hispanic ethnicity are at greater risk of both relapse and treatment-related complications. The Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium will expand and enhance an established network of childhood cancer centers, with the goal of tackling ethnic outcome disparities by generating an unmatched resource of clinical information and biological samples. This information will be used to predict those who have the greatest risk of poor outcomes, with a focus on those of Hispanic ethnicity, to improve prevention and treatment strategies.

This grant is generously supported by Micaela's Army Foundation which was established in loving memory of Micaela White who fiercely fought Acute Myeloid Leukemia at the age of 18. Their mission is to raise money to help fund cancer research, education, awareness, and patient support for the cancers that affect children and their families.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric LEukemiA Precision-based Therapy (LEAP) Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Cancer is a genetic disease caused by errors in the genomic content of tumor cells. This consortium shares, in real-time, pediatric cancer data generated by genomic studies across the world, uniting data on a variety of cancer types from diverse sources into a compendium of unprecedented scale. The consortium uses the collected data to analyze each child's cancer data against both childhood and adult patient cohorts across all types of cancer, so that this information can be used for clinical decision-making. The research team has evidence that this cross-cancer analysis can identify situations where a drug developed for another indication may work in a pediatric cancer, providing new treatment avenues and new hope to children with cancer and their families. Funds administered by University of California Santa Cruz.

This grant is named for the Emily Beazley's Kures for Kids Fund, a St. Baldrick's Hero Fund. At the age of 8, Emily was diagnosed with Stage III T-cell lymphoblastic non-Hodgkin’s lymphoma. Her cancer was extremely aggressive, and she bravely battled it through three relapses. Her family prayed for a miracle but discovered Emily herself was the miracle. She inspired a community to come together to show love and she changed lives with her message: “You gotta stay strong, you gotta stay positive, no matter what happens.” Emily passed away at age of 12. She often talked about her dream of starting a foundation that funded research and she named it “Kures for Kids”. Her family and friends carry on her dream and her mission.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Treehouse Childhood Cancer Initiative. For a description of this project, see the consortium grant made to the lead institution: University of California Santa Cruz, Santa Cruz, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric LEukemiA Precision-based Therapy (LEAP) Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric LEukemiA Precision-based Therapy (LEAP) Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric LEukemiA Precision-based Therapy (LEAP) Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric LEukemiA Precision-based Therapy (LEAP) Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.